Get the Stockscreener App
39.67
4.72%
1.95
Rapport Therapeutics Inc stock is traded at $39.67, with a volume of 122.19K.
It is up +4.72% in the last 24 hours and up +8.04% over the past month.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
See More
Previous Close:
$37.72
Open:
$38.35
24h Volume:
122.19K
Relative Volume:
0.37
Market Cap:
$1.89B
Revenue:
-
Net Income/Loss:
$-107.28M
P/E Ratio:
-15.24
EPS:
-2.6031
Net Cash Flow:
$-80.71M
1W Performance:
+14.93%
1M Performance:
+8.04%
6M Performance:
+34.22%
1Y Performance:
+265.06%
1-Day Range:
$37.67
$39.54
1-Week Range:
$33.85
$39.51
52-Week Range:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
39.54 | 1.80B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
437.68 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.73 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.73 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.60 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-02-26 | Initiated | Wells Fargo | Overweight |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
Rapport Therapeutics (RAPP) Gains 2.7% as Price Approaches Key Resistance LevelValue Factor - Newser
RAPP Maintains Buy Rating -- Price Target Raised to $65.00 by BT - GuruFocus
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
RAPP Assumes Buy Rating with Price Target Raised to $56.00 by Tr - GuruFocus
Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Rapport Therapeutics Inc (RAPP) - MSN
Truist assumes Rapport Therapeutics stock with buy on epilepsy drug By Investing.com - Investing.com Canada
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $56 - Moomoo
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
Trading the Move, Not the Narrative: (RAPP) Edition - Stock Traders Daily
Will Narrowing Losses And Per Share Improvement Reframe Rapport Therapeutics' (RAPP) Investment Narrative? - simplywall.st
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock - Investing.com
TradingKey - TradingKey
Stifel reiterates Buy on Rapport Therapeutics stock, $56 target By Investing.com - Investing.com Canada
Rapport Therapeutics(RAPP.US) 10% Shareholder Sells US$11.09 Million in Common Stock - Moomoo
Third Rock funds trim Rapport Therapeutics (RAPP) stake under Rule 10b5-1 plan - Stock Titan
Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144 - Stock Titan
Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP - MarketBeat
Third Rock sells 697,500 RAPP shares (RAPP) in April–May 2026 - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A 34% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rapport Therapeutics (NASDAQ:RAPP) Posts Earnings Results, Beats Estimates By $0.25 EPS - MarketBeat
Third Rock Ventures sells 426,005 RAPP shares (NASDAQ: RAPP) - Stock Titan
Rapport Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market - TipRanks
(RAPP) Volatility Zones as Tactical Triggers - Stock Traders Daily
Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines - ChartMill
Earnings Flash (RAPP) Rapport Therapeutics, Inc. Reports Q1 Revenue $20.0M, vs. FactSet Est of $7.5M - marketscreener.com
Rapport Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.42) — 10-Q Summary - TradingView
Collaboration deal lifts Rapport Therapeutics (NASDAQ: RAPP) revenue and cash - Stock Titan
Cash runway to 2H 2029 as Rapport (NASDAQ: RAPP) advances RAP-219 - Stock Titan
Seizure drug posted 90% cut as Rapport says cash lasts to 2029 - Stock Titan
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update - GlobeNewswire
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com
Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Rapport Therapeutics prices $250M stock at $26 per share - MSN
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail
Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan
Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart
Rapport Therapeutics Inc Stock (RAPP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 10% Owner |
May 07 '26 |
Sale |
40.12 |
271,495 |
10,892,651 |
6,437,733 |
| Third Rock Ventures V, L.P. | 10% Owner |
May 08 '26 |
Sale |
40.31 |
5,018 |
202,256 |
6,432,715 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):